報價延遲最少15分鐘:2024/12/24 12:42 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.692 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.95/-5.46
|
|
企業價值
163.23M
|
| 資產負債 |
|
每股賬面淨值
6.93
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
480.00K
|
|
每股收益
0.17
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:42 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics. |